Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (March 2023)
24 slides from Avicanna's investor presentation, Mar 14, 2023
Slide 1: Driving Biopharmaceutical Advancements
Q1 2023 Driving Biopharmaceutical Advancements of Naturally Derived and Evidence Based Products TSX: AVCN OTCQX: AVCNF FSE: 0NN avicanna.com © 2023 Avicanna Inc.
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations and other applicable sec
Slide 3: Timeline
0.1 Timeline Avicanna is a commercial and scale-up stage biopharmaceutical company established in R&D, and commercialization of evidence-based cannabinoid products for the international consumer, medical and pharmaceutical market segments. Supported by its Canadian scientific platform, Avicanna has
Slide 4: Investment Highlights
0.2 Investment Highlights Leading Scientific Platform and Intellectual Property Portfolio • Incubated JLABS @ Johnson & Johnson Innovation Centre, in the MaRS Discovery District • Canadian R&D and clinical infrastructure - in partnership with world-class institutions including UHN and U of T • 30+ p
Slide 5: Avicanna's Four Business Pillars
0.3 Avicanna’s Four Business Pillars Intellectual Property and Brands Owned by Avicanna Active Pharmaceutical Cosmetics and Skincare Medical Cannabis Pharmaceutical Pipeline Ingredients Commercial Commercial and Wellness Products In Development and Commercial Registration Stages 05 © 2023 Avicanna I
Slide 6: Scientific Platform
1. Scientific Platform R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products © 2023 Avicanna Inc.
Slide 7: Established Scientific Platform
1.1 Established Scientific Platform 30+ 10+ Proprietary Scientists Commercial Products R&D through several Health 7 Canada issued Cannabis Pending Patents Research Licenses 9 Commercial Stage Canadian Government Advanced Drug Delivery Research Grants Systems Products Awarded Since 2020 07 © 2023 Avi
Slide 8: World-Class Institutional Collaborations
1.2 World-Class Institutional Collaborations 20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017 08 © 2023 Avicanna Inc.
Slide 9: Commercial Products & Pipeline
2. Commercial Products & Pipeline Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products © 2023 Avicanna Inc.
Slide 10: RHO Phyto
Transdermal Gel Capsules Water-Soluble Tablets Infusers Local Creams Sublingual Spray 2.1 RHO Phyto Oil Drops Advanced Drug Delivery System Formulations (CBD, THC, CBG) - for International Medical and Wellness Market Segments © 2023 Avicanna Inc.
Slide 11: RHO Phyto and Medical Cannabis
2.1.1 RHO Phyto and Medical Cannabis Advanced AdvancedDrug Evidence-based Pre-clinical & Long-term Accurate & Accurate Easy Delivery with Clinical Studies Stability Consistent Dosing Dosing to Use Platforms Pre-clinical Data and Consistency & Easy to Use National Medical Channels Provincial Adult Us
Slide 12: Strategic Partnership with Medical Cannabis by Shoppers
2.1.2 Strategic Partnership with Medical Cannabis by Shoppers Nationwide Medical Cannabis Portal • Led by Canada’s leading pharmacy retailer with more than 30,000+ registered cannabis patients Avicanna X Medical Cannabis by Shoppers Partnership, since 2019 • 23 commercial SKUs across 4 brands, strat
Slide 13: Canadian Commercialization Infrastructure
2.1.3 Canadian Commercialization Infrastructure • 113 commercial listings across adult use and medical cannabis • CAPEX lean model and manufacturing partnerships with 6 Canadian licensed producers • 24 commercial SKUs across 4 brands 13 © 2023 Avicanna Inc.
Slide 14: Proprietary Formulations and Drug Candidates
2.2 Proprietary Formulations and Drug Candidates Pharmaceutical Candidates Designed to Address 5 Major Clinical Indications Sleep Eczema/ Pain Anxiety & Epilepsy Epidermolysis Management Depression Bullosa • Established scientific platform and intellectual property • Established clinical and academi
Slide 15: Trunerox 10% CBD
2.2.1 TruneroxTM 10% CBD (100 mg/ml Cannabidiol) Pharmaceutical Drug Preparation Pending Market Authorization • Pharmaceutical preparation under GMP standards with proprietary formulation with enhanced absorption • Expected marketing authorization during early 2023 in Brazil and other South American
Slide 16: Pura HW: Clinically Backed CBD Dermacosmetic Products
2.3 Pura HW: Clinically Backed CBD Dermacosmetic Products Functional Skin Care Products Addressing Global Emerging CBD Consumer Product Segment • Proprietary and patent-pending line of 13 premium topical products • Clinically backed first line of CBD topical products supported by clinical results (c
Slide 17: Aureus Santa Marta: Cannabinoids and Standardized Genetics
2.4 Aureus Santa Marta: Cannabinoids and Standardized Genetics Avicanna’s Supply Chain Business Unit and Vertical Integration Raw Material Business Unit Branded as Aureus Santa Marta • Avicanna’s low cost and consistent supply of cannabinoids for its finished products through in-house cultivation an
Slide 18: Strategic Partnerships: Al Harrington, re+PLAY and Viola
2.5 Strategic Partnerships: Al Harrington, re+PLAY and Viola Advanced Product Development for NBA Veteran and Social Equity Ambassador, Al Harrington • 10 year old lifestyle brand focused on minority • CBD topical sports recovery brand established by Al representation and social equity. Strategic pa
Slide 19: Avicanna Around the World
2.6 Avicanna Around the World Completed Sales and Exports into 19 Countries 19 © 2023 Avicanna Inc.
Slide 20: Avicanna Around the World
2.6 Avicanna Around the World Global Activity Across 19 International Markets Select Countries and Activities Below Note: The above table indicates prospective future launch dates based upon reasonable assumptions from current information, which are subject to, and contingent upon, the regulatory ap
Slide 21: Capitalization Table and Corporate Highlights
3.1 Capitalization Table and Corporate Highlights Tightly held by insiders and strategic investors Common shares: 74,952,800* Fully diluted: 106,669,466 Market capitalization $30 million* TSX: AVCN OTCQX: FSE: AVCNF 0NN As of Market Close March 10th, 2023, $0.50/share 21 © 2023 Avicanna Inc.
Slide 22: Management and Board of Directors
3.2 Management and Board of Directors Senior Management Team Senior Management Team Board of Directors Aras Azadian Dr. Karolina Urban, PhD Aras Azadian Founder and CEO Vice President, Medical & Scientific Affairs Founder and CEO Phillip Cardella Roland Álvarez Dr. Chandra Panchal, PhD Chief Financi
Slide 23: Corporate Highlights
3.3 Corporate Highlights De-risked investment - commercial stage, with key regulatory approvals and milestones achieved, with several product lines Diversified - scalable and high margin revenue streams Experienced management - proven track record since 2016 Intellectual property powerhouse - indust
Slide 24: Thank You
THANK YOU © 2023 Avicanna Inc.